Understanding chromosome aberrations through cytogenetic analysis is an integral part of current genomic medicine, playing a role in research into both constitutional disorders and cancer.
At Illumina, we collaborate with industry experts, thought leaders, and customers to develop solutions to meet your evolving research needs. Now you can perform sequencing and high-quality cytogenomic array scanning all on a single platform.
Next-generation sequencing (NGS) offers detection capabilities that complement arrays. By providing a base-by-base view of the genome, NGS can identify single nucleotide variants (SNV), small structural changes, and balanced translocations, providing researchers with a genome-wide view of chromosomal variation.
NGS can be used to confirm copy number variants detected by arrays. Together, the two methods are ideal for cytogenomic studies across a spectrum of constitutional as well as cancer research applications. Now you can perform both NGS and array scanning on a single system, the NextSeq 550 System.View NextSeq 550 System
Traditional molecular cytogenomic methods for assessing chromosomal abnormalities, including FISH and karyotyping, enable genome visualization, but generally at a low resolution. As a result, data from these methods can often be incomplete.1
Cytogenomic microarrays offer a simple, reliable method for assessing chromosomal aberrations at a higher resolution. Illumina offers industry-leading microarrays designed to detect chromosome aberrations and provide accurate, reliable cytogenomic data with:
Targeted NGS can identify myeloid-related genes with greater sensitivity than Sanger sequencing or cytogenetic methods.Read Interview
Ravindra Kolhe, MD, PhD, discusses using the TruSight RNA Fusion Panel to study gene fusions in cancer.Read Interview
Trilochan Sahoo, MD discusses the benefits of the CytoSNP-850K BeadChip for cytogenetics researchers.Read Interview